kisqali® (ribociclib) mechanism of action in metastatic breast cancer for patients
Published 3 years ago • 4.7K plays • Length 7:45Download video MP4
Download video MP3
Similar videos
-
7:23
study of ribociclib and pdr001 in hr metastatic breast cancer
-
7:14
ribociclib for hr advanced breast cancer
-
2:49
safety and efficacy of ribociclib and letrozole in advanced breast cancer – the monaleesa-2 trial
-
7:59
what are cdk 4/6 inhibitors for breast cancer?
-
1:26
ribecca: ribociclib, a cdk4/6 inhibitor in er breast cancer
-
8:28
cdk4/6 inhibition in breast cancer
-
7:18
kisqali (ribociclib): side effects and what to expect
-
12:58
the science behind kisqali: understanding how this targeted therapy works to treat cancer
-
7:21
fda approval of ribociclib for metastatic breast cancer
-
13:52
my targeted therapy experience - ribociclib/kisqali for metastatic breast cancer
-
7:13
the biological rationale for cdk4/6 inhibitors
-
1:11
using ribociclib in the first-line setting
-
8:55
researcher comment: ribociclib efficacy for visceral metastases | denise yardley
-
0:59
dr. kelly on the fda approval of ribociclib in hr breast cancer
-
4:28
cdk4/6 inhibitor maintained os benefit in advanced breast cancer - medpage today
-
2:42
eribulin as treatment for metastatic breast cancer
-
5:43
cdk 4/6 inhibitor, palbociclib, for the treatment of metastatic breast cancer
-
1:58
recent fda approval of ribociclib as upfront therapy
-
2:27
understanding abemaciclib: a new cdk4/6 inhibitor